临床试验/NCT05767866

NCT05767866招募中1 期

Safety and Preliminary Efficacy of YK-029A, a Novel EGFR TKI, in Patients With Advanced NSCLC Harboring ex20ins, T790M or Rare Mutations

Suzhou Puhe Pharmaceutical Technology Co., LTD35 个研究点分布在 1 个国家目标入组 160 人开始时间: 2018年3月30日最近更新: 2023年3月17日

适应症

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 160
试验地点: 35
主要终点: Part 1: Number of Participants with Clinically Significant Abnormal Laboratory Values.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small cell lung cancer (NSCLC).

详细描述

This phase 1/2 study will evaluate the safety, pharmacokinetics, and anti-tumor activity of oral EGFR Inhibitor YK-209A in participants with NSCLC and anti-tumor activity of YK-029A in participants with solid tumors other than NSCLC harboring ex20ins, T790M or rare mutations. The trial will be conducted in three parts: a dose escalation (Part 1), expansion phase (Part 2), followed by an extension phase (Part 3).

The objectives of the dose escalation phase (Part 1), is to determine the safety profile of orally administered YK-029A, including the MTD, DLTs, RP2D, pharmacokinetic profile. The primary goal of the expansion component of the trial is to evaluate the anti-tumor activity of YK-029A in nine histologically and molecularly defined cohorts at the RP2D (determined based on dose escalation phase of the trial).

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•General Inclusion Criteria all cohorts: dose escalation, dose expansion, and dose extension:
•Have histologically or cytologically confirmed locally advanced or metastatic NSCLC disease (Stage IIIB or IV) .
•Male or femal adult，be able to provide a signed and dated, written informed consent.
•Must have measurable disease by response evaluation criteria in solid tumors (RECIST) v1.
•Minimum life expectancy of 3 months or more.
•Adequate organ function at baseline.
•Normal QT interval on screening electrocardiogram (ECG), defined as QT interval corrected (Fridericia) (QTcF) of less than or equal to (≤ ) 450 millisecond (ms) in males or ≤ 470 ms in females.
•Part 1: Dose Escalation Cohort Specific Inclusion Criteria:
•Refractory to standard available therapies.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-65 years old.
•previously treated NSCLC patients with EGFR T790M.
•Part 2: Expansion Cohort 1、2、3 Specific Inclusion Criteria:
•previously treated NSCLC patients with EGFR T790M.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-75 years old.
•Part 2: Expansion Cohort 4、5 Specific Inclusion Criteria:
•previously treated NSCLC patients with EGFR exton 20ins.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-75 years old.
•Part 3: Expansion Cohort 6 Specific Inclusion Criteria:
•previously untreated NSCLC patients with EGFR exton 20ins.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-75 years old.
•Part 3: Expansion Cohort 7、8 Specific Inclusion Criteria:
•previously treated NSCLC patients with EGFR rare mutation(（G719X、L861Q、S768I).
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-75 years old.
•Part 3: Expansion Cohort9 Specific Inclusion Criteria:
•previously treated NSCLC patients with EGFR exton 20ins.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to
•aged 18-75 years old.

排除标准

•Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before screening.
•Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before screening.
•NSCLC patients with EGFR T790M mutation previously treated with third-generation EGFR-TKIs (such as AZD9291, CO-1686, HM61713, EGF816, PF-06747775, vometinib, BPI-15086, Ivirtinib maleate, etc.) and their apis or the same drugs in other clinical trials Drug treatment.
•Patients with NSCLC with EGFR ex20ins mutation had previously received EGFR ex20ins inhibitors and/or EGFR-cMET double antibodies (including but not limited to TAK-788, bociotinib, JNJ-61186372, DZD9008, vometinib, PLB1004, and AZD9291 in excess of the clinically approved dose (cohort 9 prohibited AZD9291 at any dose) and Drug substance or other similar drug treatment in the clinical trial stage.
•NSCLC patients with rare EGFR mutations have previously been treated with third-generation EGFR-Tkis (such as AZD9291, etc.) and their apis or other similar drugs in clinical trials.
•Received a moderate or strong CYP4503A inhibitor or moderate or strong CYP3A inducer within 10 days prior to first dose of YK-029A.
•Have significant, uncontrolled, or active cardiovascular disease.
•Have a known history of uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure.
•Have prolonged QTcF interval, or being treated with medications known to be associated with the development of torsades de pointes.
•Have an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.
•Currently have or have a history of interstitial lung disease, radiation pneumonitis that required steroid treatment, or drug-related pneumonitis.
•Female participants who are lactating and breastfeeding or have a positive urine or serum pregnancy test during the screening period.
•Note: Female participants who are lactating will be eligible if they discontinue breastfeeding.
•Have gastrointestinal illness or disorder that could affect oral absorption of YK-029A.
•Have any condition or illness that, in the opinion of the investigator, might compromise participant safety or interfere with the evaluation of the safety of the drug.
•Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

研究组 & 干预措施

Part 1: Dose Escalation Component

Experimental

In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50, 100, 150, 200 to 250 mg/day (3+3 design).

干预措施: YK-029A (Drug)

Part 2: Expansion Cohort 1

Experimental

In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 2: Expansion Cohort 2

Experimental

In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 100mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 2: Expansion Cohort 3

Experimental

In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 4

Experimental

In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 5

Experimental

In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 6

Experimental

In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 7

Experimental

In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 8

Experimental

In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)

Part 3: ExTension Cohort 9

Experimental

In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mgBID and who have no active, measurable central nervous system (CNS) metastases.

干预措施: YK-029A (Drug)